Literature DB >> 28686863

The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery.

Gary Gintant1, Bernard Fermini2, Norman Stockbridge3, David Strauss4.   

Abstract

Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2017        PMID： 28686863     DOI： 10.1016/j.stem.2017.06.005

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  29 in total

1.  Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.

Authors:  Andre Monteiro da Rocha; Jeffery Creech; Ethan Thonn; Sergey Mironov; Todd J Herron
Journal:  Toxicol Sci       Date:  2020-02-01       Impact factor: 4.849

Review 2.  Intensive care for human hearts in pluripotent stem cell models.

Authors:  Pelin Golforoush; Michael D Schneider
Journal:  NPJ Regen Med       Date:  2020-03-06

Review 3.  Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.

Authors:  Emily A Pinheiro; Tarek Magdy; Paul W Burridge
Journal:  J Cardiovasc Transl Res       Date:  2020-02-20       Impact factor: 4.132

Review 4.  hiPSCs in cardio-oncology: deciphering the genomics.

Authors:  Emily A Pinheiro; K Ashley Fetterman; Paul W Burridge
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 5.  Cardiovascular disease models: A game changing paradigm in drug discovery and screening.

Authors:  Houman Savoji; Mohammad Hossein Mohammadi; Naimeh Rafatian; Masood Khaksar Toroghi; Erika Yan Wang; Yimu Zhao; Anastasia Korolj; Samad Ahadian; Milica Radisic
Journal:  Biomaterials       Date:  2018-10-01       Impact factor: 12.479

6.  Genetic Algorithm For Fitting Cardiac Cell Biophysical Model Formulations.

Authors:  Akwasi Darkwah Akwaboah; Pascal Yamlome; Jacqueline A Treat; Jonathan M Cordeiro; Makarand Deo
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2020-07

Review 7.  Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.

Authors:  Nazish Sayed; Mohamed Ameen; Joseph C Wu
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 8.  Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.

Authors:  Dan M Roden; Sara L Van Driest; Quinn S Wells; Jonathan D Mosley; Joshua C Denny; Josh F Peterson
Journal:  Circ Res       Date:  2018-04-27       Impact factor: 17.367

9.  Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?

Authors:  Maaike Te Lintel Hekkert; Gary Newton; Dirk J Duncker; Michael D Schneider; Kathryn Chapman; Rehan Aqil; Robert Downham; Robert Yan; Daphne Merkus; Gavin Whitlock; Charlotte A L Lane; Darren Cawkill; Trevor Perrior
Journal:  Basic Res Cardiol       Date:  2021-05-20       Impact factor: 17.165

10.  An in silico hiPSC-Derived Cardiomyocyte Model Built With Genetic Algorithm.

Authors:  Akwasi D Akwaboah; Bright Tsevi; Pascal Yamlome; Jacqueline A Treat; Maila Brucal-Hallare; Jonathan M Cordeiro; Makarand Deo
Journal:  Front Physiol       Date:  2021-06-16       Impact factor: 4.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.